Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Investor Presentation (March 2015)
20 slides from Supernus Pharmaceuticals's investor presentation, March 2015
Slide 1: Investor Presentation
Investor Presentation March, 2015 © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expec
Slide 3: Commercial Stage CNS Specialty Pharma
Commercial Stage CNS Specialty Pharma Strong Execution Since 2012 IPO (dollars in millions) $115-$118* YE 2014 Revenue Guidance Product Revenue 2 CNS PRODUCTS Royalty Revenue Licensing Revenue LAUNCHED IN 2013 $76-$79* • 25-year track record of bringing products to market $39 $46 to • Successful lau
Slide 4: Proven Execution
Proven Execution 25 Years of Successful Product Development & Commercialization MARKETED PRODUCTS USING OUR 9 TECHNOLOGY & EXPERTISE 1990 1998 2001 2009 2013 2014 Carbatrol® Adderall XR® Equetro® Intuniv® Oracea® Sanctura XR® Orenitram® Note: All trademarks are the property of their respective owner
Slide 5: Strong Portfolio of CNS Products
Strong Portfolio of CNS Products Addresses $11 Billion Market Opportunity Product Indication Development NDA Launch 2013 Oxtellar XR® Epilepsy FEBRUARY 2013 Trokendi XR® Epilepsy AUGUST Impulsive Avert ® SPN-810 Aggression in Phase III Trial 2H2015 ADHD SPN-812 ADHD Phase IIb Trial 2H2015 SPN-809 De
Slide 6: Product Portfolio Opportunity
Product Portfolio Opportunity Penetrate & Gain Share of a Large Market Opportunity * Includes pediatric indications in Impulsive Aggression in ADHD, Bipolar Disorder, and Autism Source: SHA, Global Data, Company Estimates © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 6
Slide 7: Commercial Success
Commercial Success Oxtellar XR® and Trokendi XR® to Drive Future Growth © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 7
Slide 8: Oxtellar XR
Oxtellar XR® The Only Once-Daily Oxcarbazepine Product in the U.S. $17 MARKET OPPORTUNITY $17MM* 1Q to 3Q 2014 SALES $1.3B Oxtellar XR Sales ($MM) 4 Patents issued (Exp. 2027) $10 66.7 55% $7 REDUCTION IN AE-RELATED DISCONTINUATION VS. TRILEPTAL® $5 $5 30 $0 $1 Trileptal ® Oxtellar XR® 2Q13 3Q13 4Q1
Slide 9: Trokendi XR
Trokendi XR® The First Once-Daily Topiramate Product in the U.S. $42 MARKET OPPORTUNITY $42MM* 1Q to 3Q 2014 $4.5B SALES Trokendi XR Sales ($MM) 5 Patents issued (Exp. 2027) $22.6 93.4 +90% $15.3 PATIENTS PREFERRED ONCE- DAILY TROKENDI XR® OVER TWICE-DAILY TOPAMAX ® $4.1 6.6 1Q14 2Q14** 3Q14 YTD* Tr
Slide 10: Strong Prescription Growth
Strong Prescription Growth Two Successful Product Launches 70,739 1Q to 3Q 2014 Sales of 57,776 $59MM* Trokendi XR® and Oxtellar XR® 45,813 Oxtellar XR Prescriptions 50,583 Trokendi XR Prescriptions 32,063 Combined Prescriptions 39,524 22,205 30,840 8,992 20,094 12,027 3,623 588 1,549 18,252 20,156
Slide 11: Robust, Late-Stage Pipeline
Robust, Late-Stage Pipeline Fueling Sustainable, Long-term Growth © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 11
Slide 12: Robust, Late-Stage Pipeline
Robust, Late-State Pipeline Addresses $5.5 Billion Market Opportunity Product Indication Development NDA Launch Oxtellar XR® Epilepsy Trokendi XR® Epilepsy Impulsive Avert ® SPN-810 Aggression in Phase III Trial 2H2015 ADHD SPN-812 ADHD Phase IIb Trial 2H2015 SPN-809 Depression © 2015 Supernus Pharm
Slide 13: SPN-810 Novel Product for Impulsive Aggression
SPN-810 Novel Product for Impulsive Aggression (IA) +$3B ADDRESSABLE OPPORTUNITY MARKET ADHD $1.5 BILLION Disorder with impairment of self regulation AUTISM $1.0 BILLION Characterized by episodes of $0.6 BILLION unplanned, maladaptive aggression BIPOLAR DISORDER Currently no FDA-approved treatments
Slide 14: SPN-810 Impulsive Aggression in ADHD
SPN-810 Novel Product for Impulsive Aggression (IA) in ADHD Granted Fast Track CHILDREN WITH ADHD HAVE Development Designation 25% PERSISTENT CONDUCT PROBLEMS SUCH AS IMPULSIVE AGGRESSION 1st Expected to be first product approved to treat IA Established safety and efficacy at low and medium doses in
Slide 15: SPN-812 Novel Non-Stimulant Product for ADHD
SPN-812 Novel Non-Stimulant Product for ADHD $2.5B ADDRESSABLE MARKET ADHD AFFECTS 6% - 9% OPPORTUNITY* OF ALL SCHOOL-AGE CHILDREN… Expected to have a better AE profile than current therapies Extended-release formulation selected for the product to be used in the pivotal trials AND 3% - 5% OF ALL AD
Slide 16: Financial Overview
Successful Commercial Business within 2 Years Financial Overview © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 16
Slide 17: Strong Operating Performance
Strong Operating Performance Solid Revenue Growth Since Product Launches (dollars in millions) $115-$118* 2 YE 2014 Revenue $91MM Guidance Product Revenue Royalty Revenue Licensing Revenue 1Q to 3Q 2014 REVENUE $76-$79* $39 $46 to $115MM 118MM* TO 2014 COMPANY GUIDANCE $49 $37 $30 94.1% $12 3Q14 GRO
Slide 18: Strong Operating Performance: Quarterly Improvement in Cash Burn
Strong Operating Performance Quarterly Improvement in Cash Burn (dollars in millions) $20 $20 $19 $16 $12 $8 $5 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14* Reported as of 3Q14 * Excludes $30MM royalty monetization receipt. © 2015 Supernus Pharmaceuticals, Inc. All Rights Reserved. 18
Slide 19: Strong Balance Sheet
Strong Balance Sheet Solid Cash Position Supports Path to Profitability Cash & Cash Equivalents (dollars in millions) $88 $85MM* $63 CASH-FLOW BREAKEVEN BY END OF 2014* 2Q14 3Q14 Reported as of 3Q14 * Based on guidance produced as of November 12, 2014, which has not been updated since that date. © 2
Slide 20: Going Forward: Positioned for Continued Growth
Going Forward Positioned for Continued Growth CONTINUE GROWTH & PROFITABILITY Trokendi XR and Oxtellar XR peak sales potential of $400-500 million ADVANCE PIPELINE TOWARD COMMERCIALIZATION Advancing both SPN-810 and SPN-812 into pivotal trials TARGET STRATEGIC BUSINESS DEVELOPMENT OPPORTUNITIES Exec
Supernus Pharmaceuticals — Investor Presentation (March 2015) on 6ix